196 related articles for article (PubMed ID: 37351831)
1. Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials.
Smith SD; Stratigos A; Augustin M; Carrascosa JM; Grond S; Riedl E; Xu W; Patel H; Lebwohl M
Dermatol Ther (Heidelb); 2023 Aug; 13(8):1773-1787. PubMed ID: 37351831
[TBL] [Abstract][Full Text] [Related]
2. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
3. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials.
Genovese MC; Mysler E; Tomita T; Papp KA; Salvarani C; Schwartzman S; Gallo G; Patel H; Lisse JR; Kronbergs A; Leage SL; Adams DH; Xu W; Marzo-Ortega H; Lebwohl MG
Rheumatology (Oxford); 2020 Dec; 59(12):3834-3844. PubMed ID: 32449924
[TBL] [Abstract][Full Text] [Related]
4. Safety of Ixekizumab in Adult Patients with Moderate-to-Severe Psoriasis: Data from 17 Clinical Trials with Over 18,000 Patient-Years of Exposure.
Griffiths CEM; Gooderham M; Colombel JF; Terui T; Accioly AP; Gallo G; Zhu D; Blauvelt A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1431-1446. PubMed ID: 35624407
[TBL] [Abstract][Full Text] [Related]
5. Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure.
Armstrong A; Paul C; Puig L; Boehncke WH; Freeman M; Torii H; Papp K; Griffiths CEM; Blauvelt A; Reich K; Gooderham M; Terui T; Renda L; Agada N; Xu W; Gallo G; Lebwohl MG
Dermatol Ther (Heidelb); 2020 Feb; 10(1):133-150. PubMed ID: 31749092
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: an integrated analysis from 11 clinical trials.
Langley RG; Kimball AB; Nak H; Xu W; Pangallo B; Osuntokun OO; Agada N; Reich K
J Eur Acad Dermatol Venereol; 2019 Feb; 33(2):333-339. PubMed ID: 30198588
[TBL] [Abstract][Full Text] [Related]
7. Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis.
Combe B; Rahman P; Kameda H; Cañete JD; Gallo G; Agada N; Xu W; Genovese MC
Arthritis Res Ther; 2020 Jan; 22(1):14. PubMed ID: 31964419
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials.
Leonardi C; Reich K; Foley P; Torii H; Gerdes S; Guenther L; Gooderham M; Ferris LK; Griffiths CEM; ElMaraghy H; Crane H; Patel H; Burge R; Gallo G; Shrom D; Leung A; Lin CY; Papp K
Dermatol Ther (Heidelb); 2020 Jun; 10(3):431-447. PubMed ID: 32200512
[TBL] [Abstract][Full Text] [Related]
9. Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial.
Paller AS; Seyger MMB; Magariños GA; Pinter A; Cather JC; Rodriguez-Capriles C; Zhu D; Somani N; Garrelts A; Papp KA;
JAMA Dermatol; 2022 May; 158(5):533-541. PubMed ID: 35416908
[TBL] [Abstract][Full Text] [Related]
10. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure.
Deodhar AA; Combe B; Accioly AP; Bolce R; Zhu D; Gellett AM; Sprabery AT; Burmester GR
Ann Rheum Dis; 2022 Jul; 81(7):944-950. PubMed ID: 35393269
[TBL] [Abstract][Full Text] [Related]
11. Infections from seven clinical trials of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriasis.
Papp KA; Bachelez H; Blauvelt A; Winthrop KL; Romiti R; Ohtsuki M; Acharya N; Braun DK; Mallbris L; Zhao F; Xu W; Walls CD; Strober B
Br J Dermatol; 2017 Dec; 177(6):1537-1551. PubMed ID: 28600810
[TBL] [Abstract][Full Text] [Related]
12. Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials.
Reich K; Leonardi C; Langley RG; Warren RB; Bachelez H; Romiti R; Ohtsuki M; Xu W; Acharya N; Solotkin K; Colombel JF; Hardin DS
J Am Acad Dermatol; 2017 Mar; 76(3):441-448.e2. PubMed ID: 28027825
[TBL] [Abstract][Full Text] [Related]
13. Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials.
Mease P; Roussou E; Burmester GR; Goupille P; Gottlieb A; Moriarty SR; Benichou O; Adams DH; Xu W; Nash P
Arthritis Care Res (Hoboken); 2019 Mar; 71(3):367-378. PubMed ID: 30156760
[TBL] [Abstract][Full Text] [Related]
14. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J;
Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225
[TBL] [Abstract][Full Text] [Related]
15. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
[TBL] [Abstract][Full Text] [Related]
16. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis.
Gordon KB; Leonardi CL; Lebwohl M; Blauvelt A; Cameron GS; Braun D; Erickson J; Heffernan M
J Am Acad Dermatol; 2014 Dec; 71(6):1176-82. PubMed ID: 25242558
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2).
Orbai AM; Gratacós J; Turkiewicz A; Hall S; Dokoupilova E; Combe B; Nash P; Gallo G; Bertram CC; Gellett AM; Sprabery AT; Birt J; Macpherson L; Geneus VJ; Constantin A
Rheumatol Ther; 2021 Mar; 8(1):199-217. PubMed ID: 33278016
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS).
Paller AS; Seyger MMB; Alejandro Magariños G; Bagel J; Pinter A; Cather J; Keller S; Rodriguez Capriles C; Gontijo Lima R; Gallo G; Little CA; Edson-Heredia E; Li L; Xu W; Papp K;
Br J Dermatol; 2020 Aug; 183(2):231-241. PubMed ID: 32316070
[TBL] [Abstract][Full Text] [Related]
19. Ixekizumab 80 mg Every 2 Weeks Treatment Beyond Week 12 for Japanese Patients with Generalized Pustular Psoriasis and Erythrodermic Psoriasis.
Morita A; Okubo Y; Morisaki Y; Torisu-Itakura H; Umezawa Y
Dermatol Ther (Heidelb); 2022 Feb; 12(2):481-494. PubMed ID: 34967916
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis.
Gordon KB; Lebwohl M; Papp KA; Bachelez H; Wu JJ; Langley RG; Blauvelt A; Kaplan B; Shah M; Zhao Y; Sinvhal R; Reich K
Br J Dermatol; 2022 Mar; 186(3):466-475. PubMed ID: 34652810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]